tert-butyl 4-[4-amino-6-(pyrazin-2-ylamino)-2,4'-bipyridin-2'-yl]piperazine-1-carboxylate | 1370453-11-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-[4-amino-6-(pyrazin-2-ylamino)-2,4'-bipyridin-2'-yl]piperazine-1-carboxylate
• 英文别名: Tert-butyl 4-[4-[4-amino-6-(pyrazin-2-ylamino)pyridin-2-yl]pyridin-2-yl]piperazine-1-carboxylate
• CAS: 1370453-11-4
• 化学式: C₂₃H₂₈N₈O₂
• 分子量: 448.528
• InChiKey: RRCNECBIRVOUMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[4-amino-6-(pyrazin-2-ylamino)-2,4'-bipyridin-2'-yl]piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 2'-piperazin-1-yl-N⁶-pyrazin-2-yl-2,4'-bipyridine-4,6-diamine
  参考文献：
  名称：

  Highly potent aminopyridines as Syk kinase inhibitors

  摘要：

  A novel class of potent Syk inhibitors has been developed from rational design. Highly potent aminopyridine derivatives bearing a 4-trifluoromethyl-2-pyridyl motif and represented by compound 13b IC50: 0.6 nM were identified. Substitution by a 2-pyrazinyl motif and SAR expansion in position 4 of the central core provided diverse potent non-cytotoxic Syk inhibitors showing nanomolar activity inhibiting human mast cell line LAD2 degranulation. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.045
• 作为产物：
  描述：

  2,6-二氯-4-硝基吡啶 在 tris-(dibenzylideneacetone)dipalladium(0) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 铁粉 、 sodium carbonate 、 氯化铵 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 甲苯 为溶剂， 生成 tert-butyl 4-[4-amino-6-(pyrazin-2-ylamino)-2,4'-bipyridin-2'-yl]piperazine-1-carboxylate
  参考文献：
  名称：

  Highly potent aminopyridines as Syk kinase inhibitors

  摘要：

  A novel class of potent Syk inhibitors has been developed from rational design. Highly potent aminopyridine derivatives bearing a 4-trifluoromethyl-2-pyridyl motif and represented by compound 13b IC50: 0.6 nM were identified. Substitution by a 2-pyrazinyl motif and SAR expansion in position 4 of the central core provided diverse potent non-cytotoxic Syk inhibitors showing nanomolar activity inhibiting human mast cell line LAD2 degranulation. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.045

文献信息

• [EN] PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE ET D'ISOQUINOLÉINE EN TANT QU'INHIBITEURS DES SYK- ET JAK-KINASES
  申请人：ALMIRALL SA

  公开号：WO2012041476A1

  公开（公告）日：2012-04-05

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

  本发明涉及一种化合物（I）的公式，用于制备这种化合物的方法以及它们在治疗对Syk激酶和/或Janus激酶抑制有改善作用的病理条件或疾病中的应用。
• Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
  申请人：Almirall, S.A.

  公开号：EP2441755A1

  公开（公告）日：2012-04-18

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

  本发明涉及一种化合物的公式(I)，以及制备这种化合物的过程，以及它们在治疗一种病理状况或疾病中的应用，该病理状况或疾病容易通过抑制Syk激酶和/或Janus激酶来改善。
• Highly potent aminopyridines as Syk kinase inhibitors
  作者：Marcos Castillo、Pilar Forns、Montse Erra、Marta Mir、Manel López、Mónica Maldonado、Adelina Orellana、Cristina Carreño、Isabel Ramis、Montserrat Miralpeix、Bernat Vidal

  DOI：10.1016/j.bmcl.2012.07.045

  日期：2012.9

  A novel class of potent Syk inhibitors has been developed from rational design. Highly potent aminopyridine derivatives bearing a 4-trifluoromethyl-2-pyridyl motif and represented by compound 13b IC50: 0.6 nM were identified. Substitution by a 2-pyrazinyl motif and SAR expansion in position 4 of the central core provided diverse potent non-cytotoxic Syk inhibitors showing nanomolar activity inhibiting human mast cell line LAD2 degranulation. (C) 2012 Elsevier Ltd. All rights reserved.